What's in ASST Fatebenefratelli Sacco's pipeline?

ASST Fatebenefratelli Sacco has 7 drugs in our index: 3 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ASST Fatebenefratelli Sacco's portfolio?

Top competitors by shared drug class: ANRS, Emerging Infectious Diseases, Bamrasnaradura Infectious Diseases Institute, Christopher J. McLeod, French National Agency for Research on AIDS and Viral Hepatitis, HAL Allergy.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/asst-fatebenefratelli-sacco.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

ASST Fatebenefratelli Sacco — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ASST Fatebenefratelli Sacco pipeline: 3 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Hyoscine N-Butil Bromide	Hyoscine N-Butil Bromide	marketed
Ibuprofen 400 mg	Ibuprofen 400 mg	marketed
low-volume PEG -ascorbic acid	low-volume PEG -ascorbic acid	marketed
continue the PI/r-containing HAART.	continue the PI/r-containing HAART.	phase 3	Protease inhibitor	HIV-1 protease	Infectious disease
RPV + DRV/r	RPV + DRV/r	phase 3	Antiretroviral combination (NNRTI + protease inhibitor)	HIV reverse transcriptase; HIV protease	Infectious Disease / Virology
Slit One	Slit One	phase 3
Slit One ragweed	Slit One ragweed	phase 3	Sublingual immunotherapy (SLIT)	Ragweed allergen (Amb a 1 and related epitopes)	Immunology / Allergy

Therapeutic area mix

Immunology / Allergy · 1
Infectious Disease / Virology · 1
Infectious disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ANRS, Emerging Infectious Diseases · 1 shared drug class
Bamrasnaradura Infectious Diseases Institute · 1 shared drug class
Christopher J. McLeod · 1 shared drug class
French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
HAL Allergy · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
Janssen R&D Ireland · 1 shared drug class
ALK-Abelló A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ASST Fatebenefratelli Sacco:

Cite this brief

Drug Landscape (2026). ASST Fatebenefratelli Sacco — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asst-fatebenefratelli-sacco. Accessed 2026-05-17.